PCM
PETX

Piermont Capital Management’s Aratana Therapeutics, Inc. PETX Stock Holding History

Piermont Capital Management’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-56,734
Closed -$407K – 287
2016
Q4 		$407K Sell
56,734
-1,100
-2% -$8.89K 0.09% 242
2016
Q3 		$541K Buy
+57,834
New +$480K 0.13% 229

Other funds holding PETX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Piermont Capital Management's PETX Position: Q1 2017 in Review

Piermont Capital Management sold out of Aratana Therapeutics, Inc. (PETX) in Q1 2017, closing a stake of 56,734 shares — an estimated $407K sold.

Piermont Capital Management first reported a position in PETX in Q3 2016 and held it in 2 quarters. The position peaked at $541K in Q3 2016. 98 funds tracked by Wall St. Rank hold PETX as of Q1 2017.

  • Piermont Capital Management reported no remaining Aratana Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
  • Piermont Capital Management sold 56,734 Aratana Therapeutics, Inc. shares in Q1 2017, an estimated $407K.
  • Piermont Capital Management first reported a position in Aratana Therapeutics, Inc. in Q3 2016 and held it in 2 quarters.
  • Piermont Capital Management's Aratana Therapeutics, Inc. position peaked at $541K in Q3 2016.
  • 98 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q1 2017.

Based on Piermont Capital Management's 13F filing for Q1 2017, filed 11 May 2017.